Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2708 Target Snapshot

Mitogen-activated protein kinase kinase kinase 11 · SINGLE PROTEIN · Homo sapiens

941Compounds
273Assays
13Approved Drugs
867.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Mitogen-activated protein kinase kinase kinase 11 shows clinical signal disease relevance led by Parkinson disease. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q16584. Start with Parkinson disease, then reuse UniProt Q16584 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Parkinson disease, then reuse UniProt Q16584 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
Parkinson disease

Mitogen-activated protein kinase kinase kinase 11 shows clinical signal disease relevance led by Parkinson disease. 1 linked drug remains visible in the same block.

Start review with Parkinson disease because it currently carries clinical signal support. Linked drugs include CEP-1347. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Mitogen-activated protein kinase kinase kinase 11 as ChEMBL target CHEMBL2708, mapped to UniProt Q16584. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Mitogen-activated protein kinase kinase kinase 11
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2708
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q16584
Mitogen-activated protein kinase kinase kinase 11
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Mitogen-activated protein kinase kinase kinase 11 is the right protein anchor across sources, using UniProt Q16584 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Parkinson disease is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelMitogen-activated protein kinase kinase kinase 11
UniProt AccessionQ16584
Component TypeProtein
Sequence Length847 aa

Mitogen-activated protein kinase kinase kinase 11

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Mitogen-activated protein kinase kinase kinase 11, mapped to UniProt Q16584. Sequence length is 847 aa.

Mapped IDQ16584
Review nameMitogen-activated protein kinase kinase kinase 11
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Mitogen-activated protein kinase kinase kinase 11 shows clinical signal disease relevance led by Parkinson disease.

Clinical signal Phase II
Parkinson disease
1 linked drug · 1 direct · 1 efficacy
Linked drugCEP-1347
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with Parkinson disease because it currently carries clinical signal support. Linked drugs include CEP-1347. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseParkinson disease
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

13
Approved
6
Phase III
13
Phase II
12
Phase I
Assay Mix

Activity Type Distribution

IC50491.0
KD376.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL388978 8.61 IC50 2.47 Preclinical
CHEMBL2436980 8.52 IC50 3.0 Preclinical
CHEMBL4465866 8.52 Kd 3.0 Preclinical
CHEMBL4576489 8.4 Kd 4.0 Preclinical
CHEMBL281948 8.3 IC50 5.0 Preclinical
CHEMBL290352 8.22 IC50 6.0 Clinical
CHEMBL5397520 8.22 IC50 6.0 Preclinical
CHEMBL5403058 8.22 IC50 6.0 Preclinical
CHEMBL2436982 8.15 IC50 7.0 Preclinical
CHEMBL4218417 8.15 IC50 7.0 Preclinical
Distribution

pChEMBL Value Distribution

9
5.0
34
5.5
170
6.0
20
6.5
22
7.0
38
7.5
12
8.0
3
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

GILTERITINIB
CHEMBL3301622
Approved 2018
ENCORAFENIB
CHEMBL3301612
Approved 2018
MIDOSTAURIN
CHEMBL608533
Approved 2017
NINTEDANIB
CHEMBL502835
Approved 2014
DABRAFENIB
CHEMBL2028663
Approved 2013
PAZOPANIB
CHEMBL477772
Approved 2009
Assay Landscape

Assay Landscape

273
Total Assays
226
Tested Compounds
1
Assay Types
Binding — 273 assays, 226 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 194 163 6.5
cell-based format 30 5 8.1
subcellular format 26 39 6.0
assay format 23 19 7.1

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine